Is osimertinib effective as a first-line drug in the treatment of brain metastases from non-small cell lung cancer?

Osimertinib has a remarkable effect in treating brain metastases from non-small cell lung cancer (NSCLC) and is known as the "anti-cancer miracle drug".

Osimertinib is a third-generation irreversible oralEGFR-TKI (epidermal growth factor receptor- tyrosine kinase inhibitor enzyme inhibitor), which can effectively and selectively inhibit EGFR-TKI-related resistance mutations, such as the T790M mutation. These mutations have been shown to be effective in NSCLC central nervous system metastasis. Compared with the first and second generation EGFR-TKIs, osimertinib has higher brain permeability and can significantly penetrate the blood-brain barrier, thus showing excellent efficacy in the treatment of brain metastases.

Clinical studies have shown that osimertinib is effective as high as 70% in treating brain metastases from non-small cell lung cancer, and can significantly reduce the risk of brain metastasis progression. For example, inAURA3 In a phase III study, osimertinib significantly prolonged the progression-free survival (PFS) of T790M-positive patients compared with platinum doublet chemotherapy. Consistent efficacy was observed in all established subgroups including CNS metastasis. In addition, the median progression-free survival of osimertinib in patients with brain metastases can reach 22.1 months, demonstrating its durable efficacy in the treatment of brain metastases.

Osimertinib not only performs well in the treatment of brain metastases, but also effectively prolongs the overall survival of patients. In the ADAURA study, osimertinib was used as postoperative adjuvant therapy to significantly extend the disease-free survival of patients with non-small cell lung cancer carrying EGFR mutations. time (DFS), and the predicted patient 5 annual survival rate reaches 83.2%. This data is unprecedented in the current field of lung cancer research and brings more hope for cure to patients after lung cancer surgery.

It should be noted that osimertinib is not suitable for all patients with lung cancer and brain metastases. Its efficacy depends on the specific circumstances of the patient, including pathological type, genotype, metastasis site, and severity of the disease. Therefore, when using osimertinib to treat lung cancer brain metastases, it is necessary to comprehensively consider the patient's specific situation, formulate a personalized treatment plan, conduct close monitoring and evaluation during the treatment process, and adjust the treatment plan in a timely manner.

As a targeted drug, although the side effects of osimertinib are relatively minor, it may still produce some adverse reactions, such as diarrhea, rash, and oral ulcers. Patients need to regularly monitor liver and kidney function and other related indicators during use to ensure efficacy and safety.